Vitamin B for patients on anti‑TB meds
• Recommendation: Give pyridoxine (vitamin B6) 25–50 mg daily with isoniazid to all patients at increased neuropathy risk; if neuropathy develops, increase to 100 mg daily. 1, 2, 1
Who must receive B6 (give 25–50 mg/day from day 1):
Dose adjustments:
Rationale tied to morbidity, mortality, QoL:
- Prevents INH‑associated peripheral neuropathy, seizures, and neurotoxicity, which impair function and adherence, risking treatment failure and death. Multiple ATS/CDC/IDSA guidelines consistently endorse prophylaxis in at‑risk groups; the 2025 update strengthens to all patients on INH receiving 25–50 mg/day, aligning with safety and prevention priorities [4; corroborated by 1,2].
- Biologic evidence shows INH lowers active B6 (PLP) levels rapidly; supplementation prevents deficiency and neuropathy 5.
Practical algorithm:
- If any risk factor present (see list above) or per 2025 ATS/CDC/ERS/IDSA update: start pyridoxine 25–50 mg/day with INH the same day therapy begins [4; 1,2].
- Monitor for paresthesias, burning feet, weakness; if present, increase to 100 mg/day and assess for other causes; continue INH if tolerated 1, 2.
- In pregnancy/breastfeeding: ensure mother 25–50 mg/day; give infant pyridoxine supplement while breastfeeding if mother on INH 1, 3.
- Continue B6 for the entire duration of INH therapy; stop when INH stops.
Pitfalls/caveats:
- Do not rely on multivitamins alone—often <25 mg B6; prescribe dedicated pyridoxine 6.
- Very high chronic B6 (>200 mg/day) may cause sensory neuropathy; stay within guideline doses (25–50 mg/day; 100 mg/day if symptomatic) [general safety; guideline dosing 1,2].
- Children: routine prophylaxis is not universally mandated in all children, but give to breastfeeding infants and those with dietary risk or symptoms; many clinicians extend prophylaxis to high‑risk pediatric patients given safety and prevention benefits 3. The 2025 guideline table supports 25–50 mg/day with INH broadly, which can be applied with pediatric dosing considerations 4.
Scope: